The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
Open accessAbstract
The success of the tyrosine kinase imatinib inhibitor (Gleevec, STI571) in treating chronic myeloid leukemia as well as other selected cancers has greatly increased optimism for the broader application of kinase inhibitor therapy in cancer. To date, however, imatinib remains the only spectacularly successful example. Is it simply a matter of time before kinase inhibitors become more broadly useful? Or is chronic myeloid leukemia a unique disease that does not reflect the true genetic complexity of other cancers? Here I address this question by summarizing the growing evidence that kinase inhibitor therapy works consistently and reliably against cancers in which the kinase drug target is constitutively activated by gene mutation. I also discuss the prospects for extending this concept more broadly—to other cancers in which kinase pathways are activated directly by kinase gene mutation or indirectly by loss of negative regulatory proteins (i.e., phosphatases such as the PTEN tumor suppressor). Finally, I give my perspective on how future drug discovery and clinical trial design programs in molecularly targeted therapy could be modified based on present clinical experience with kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Again, beneficial effects were quickly apparent, because a large fraction of patients had complete or partial remissions (van Oosterom et al. 2001; Demetri et al. 2002).”
BackgroundThe phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Self-citationTSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationManning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555 · cited 1×
“However, genetic and biochemical evidence from several model systems has now established that Akt can regulate TOR through phosphorylation of the tuberous sclerosis complex (Inoki et al. 2002; Manning et al. 2002; Potter et al. 2002).”
Background
Cited by
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Self-citationG1 cell-cycle control and cancer
Massagué, J. (2004) · Nature · doi:10.1038/nature03094 · Cited by 1,224
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Self-citationIntragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
EGFR Mutations in Lung Cancer: Correlation With Clinical Response to Gefitinib Therapy
Tanoue, L. T. (2006) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(08)70092-6 · Cited by 776
Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639
Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222034 · Cited by 634
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Zhu, C., Wei, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1090-3 · Cited by 488
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
An In vivo Platform for Translational Drug Development in Pancreatic Cancer
Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio-Donahue, C., Karikari, C., Shi, C., Danenberg, K., Danenberg, P. V., Kuramochi, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0113 · Cited by 414
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1486 · Cited by 411
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Giordano, T. J., Kuick, R., Thomas, D. G., Misek, D. E., Vinco, M., Sanders, D., Zhu, Z., Ciampi, R., Roh, M., Shedden, K., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208822 · Cited by 383
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 367
Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 352
Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
Self-citationWang, M. Y., Lu, K. V., Zhu, S., Dia, E. Q., Vivanco, I., Shackleford, G. M., Cavenee, W. K., Mellinghoff, I. K., Cloughesy, T. F., Sawyers, C. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4392 · Cited by 240
Self-citationThe c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Regulation of efferocytosis as a novel cancer therapy
Zhou, Y., Yao, Y., Deng, Y., & Shao, A. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00542-9 · Cited by 100
Metadata
- Authors
- Sawyers, C. L.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-12-15
- Volume
- 17
- Issue
- 24
- Pages
- 2998-3010
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2153810740
- Cited by
- 170
- References
- 7
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.